抗结核药品临床试验疗效评价指标的研究进展

doi:10.3969/j.issn.1000-6621.2021.01.018

摘要/Abstract

摘要：

评价抗结核药品疗效的方法,需要其指标能准确预测灭菌效果和杀菌效果。传统抗结核药品临床试验Ⅱ期临床试验采用早期杀菌活性和痰分枝杆菌培养阴转预测杀菌效果和灭菌效果,Ⅲ期临床试验用已治愈且无复发来评价疗效。新的研究显示,痰培养阴转速度、CT和正电子发射体层摄影(positron emission tomography,PET)-CT病灶定量分析和GeneXpert MTB/RIF的循环阈值在预测抗结核药品疗效方面有一定价值。

关键词: 抗结核药, 临床试验,Ⅱ期, 临床试验,Ⅲ期, 药物评价,临床前

Abstract:

Bactericidal activity and sterilizing activity should be evaluated in clinical trials of novel antituberculosis agents. Early bactericidal activity and sputum culture conversion used to be main indicators for evaluating clinical responses in phase Ⅱ trials, while cure without relapse were frequently used as endpoint in phase Ⅲ trials. Recent studies showed that sputum culture conversion time, quantification of CT and PET-CT lesions and GeneXpert MTB/RIF threshold cycle could be used as surrogate endpoints of clinical trials.

Key words: Antitubercular agents, Clinical trial,phase Ⅱ, Clinical trial,phase Ⅲ, Drug evaluation,preclinical

段鸿飞, 初乃惠. 抗结核药品临床试验疗效评价指标的研究进展[J]. 中国防痨杂志, 2021, 43(1): 96-99. doi: 10.3969/j.issn.1000-6621.2021.01.018

DUAN Hong-fei, CHU Nai-hui. Research progress of clinical endpoints in clinical trials of novel antituberculosis agents[J]. Chinese Journal of Antituberculosis, 2021, 43(1): 96-99. doi: 10.3969/j.issn.1000-6621.2021.01.018

参考文献 28

[1]	Wallis RS, Kim P, Cole S, et al. Tuberculosis biomarkers discovery: developments, needs, and challenges. Lancet Infect Dis, 2013,13(4):362-372. doi: 10.1016/S1473-3099(13)70034-3. doi: 10.1016/S1473-3099(13)70034-3 URL
[2]	Wallis RS, Pai M, Menzies D, et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet, 2010,375(9729):1920-1937. doi: 10.1016/S0140-6736(10)60359-5. doi: 10.1016/S0140-6736(10)60359-5 URL pmid: 20488517
[3]	Wallis RS, Maeurer M, Mwaba P, et al. Tuberculosis-advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. Lancet Infect Dis, 2016,16(4):e34-46. doi: 10.1016/S1473-3099(16)00070-0. doi: 10.1016/S1473-3099(16)00070-0 URL pmid: 27036358
[4]	Perrin FMR, Lipman MCI, McHugh TD, et al. Biomarkers of treatment response in clinical trials of novel antituberculosis agents. Lancet Infect Dis, 2007,7(7):481-490. doi: 10.1016/S1473-3099(07)70112-3. doi: 10.1016/S1473-3099(07)70112-3 URL
[5]	Jindani A, Aber VR, Edwards EA, et al. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis, 1980,121(6):939-949. doi: 10.1164/arrd.1980.121.6.939. doi: 10.1164/arrd.1980.121.6.939 URL pmid: 6774638
[6]	Rustomjee R, Diacon AH, Allen J, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother, 2008,52(8):2831-2835. doi: 10.1128/AAC.01204-07. doi: 10.1128/AAC.01204-07 URL pmid: 18505852
[7]	Mitchison DA. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis, 1993,147(4), 1062-1063. doi: 10.1164/ajrccm/147.4.1062. doi: 10.1164/ajrccm/147.4.1062 URL pmid: 8466107
[8]	Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med, 2014,371(17):1577-1587. doi: 10.1056/NEJMoa1407426. doi: 10.1056/NEJMoa1407426 URL pmid: 25196020
[9]	Horne DJ, Royce SE, Gooze L, et al. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect Dis, 2010,10(6):387-394. doi: 10.1016/S1473-3099(10)70071-2. doi: 10.1016/S1473-3099(10)70071-2 URL
[10]	Kurbatova EV, Cegielski JP, Lienhardt C, et al. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort stu-dies. Lancet Respir Med, 2015,3(3):201-209. doi: 10.1016/S2213-2600(15)00036-3. doi: 10.1016/S2213-2600(15)00036-3 URL
[11]	Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med, 2014,371(8):723-732. doi: 10.1056/NEJMoa1313865. doi: 10.1056/NEJMoa1313865 URL pmid: 25140958
[12]	Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med, 2012,366(23):2151-2160. doi: 10.1056/NEJMoa1112433. doi: 10.1056/NEJMoa1112433 URL pmid: 22670901
[13]	Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med, 2012,367(16):1508-1518. doi: 10.1056/NEJMoa1201964. doi: 10.1056/NEJMoa1201964 URL pmid: 23075177
[14]	Conradie F, Diacon AH, Ngubane N, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med, 2020,382(10):893-902. doi: 10.1056/NEJMoa1901814. doi: 10.1056/NEJMoa1901814 URL pmid: 32130813
[15]	Marx FM, Dunbar R, Enarson DA, et al. The temporal dynamics of relapse and reinfection tuberculosis after successful treatment: a retrospective cohort study. Clin Infect Dis, 2014,58(12):1676-1683. doi: 10.1093/cid/ciu186. doi: 10.1093/cid/ciu186 URL
[16]	Nsofor CA, Jiang Q, Wu J, et al. Transmission is a Noticeable Cause of Resistance Among Treated Tuberculosis Patients in Shanghai, China. Sci Rep, 2017,7(1):7691. doi: 10.1038/s41598-017-08061-3. doi: 10.1038/s41598-017-08061-3 URL pmid: 28794425
[17]	Li X, Zhang Y, Shen X, et al. Transmission of drug-resistant tuberculosis among treated patients in Shanghai, China. J Infect Dis, 2007,195(6):864-869. doi: 10.1086/511985. doi: 10.1086/511985 URL pmid: 17299717
[18]	Nunn AJ, Phillips PPJ, Meredith SK, et al. A trial of a shorter regimen for rifampin-resistant tuberculosis. N Engl J Med, 2019,380(13):1201-1213. doi: 10.1056/NEJMoa1811867. doi: 10.1056/NEJMoa1811867 URL pmid: 30865791
[19]	Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med, 2009,360(23):2397-2405. doi: 10.1056/NEJMoa0808427. doi: 10.1056/NEJMoa0808427 URL pmid: 19494215
[20]	von Groote-Bidlingmaier F, Patientia R, Sanchez E, et al. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. Lancet Respir Med, 2019,7(3):249-259. doi: 10.1016/S2213-2600(18)30426-0. doi: 10.1016/S2213-2600(18)30426-0 URL pmid: 30630778
[21]	Chen RY, Dodd LE, Lee M, et al. PET/CT imaging correlates with treatment outcome in patients with multidrug-resis-tant tuberculosis. Sci Transl Med, 2014,6(265):265ra166. doi: 10.1126/scitranslmed.3009501. doi: 10.1126/scitranslmed.3009501 URL pmid: 25473034
[22]	Coleman MT, Chen RY, Lee M, et al. PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis. Sci Transl Med, 2014,6(265):265ra167. doi: 10.1126/scitranslmed.3009500. doi: 10.1126/scitranslmed.3009500 URL pmid: 25473035
[23]	Coleman MT, Maiello P, Tomko J, et al. Early Changes by (18)Fluorodeoxyglucose positron emission tomography coregistered with computed tomography predict outcome after Mycobacterium tuberculosis infection in cynomolgus macaques. Infect Immun, 2014,82(6):2400-2404. doi: 10.1128/IAI.01599-13. doi: 10.1128/IAI.01599-13 URL
[24]	Lin PL, Coleman T, Carney JPJ, et al. Radiologic responses in cynomolgous macaques for assessing tuberculosis chemotherapy regimens. Antimicrob Agents Chemother, 2013,57(9):4237-4244. doi: 10.1128/AAC.00277-13. doi: 10.1128/AAC.00277-13 URL pmid: 23796926
[25]	Friedrich SO, Rachow A, Saathoff E, et al. Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. Lancet Respir Med, 2013,1(6):462-470. doi: 10.1016/S2213-2600(13)70119-X. doi: 10.1016/S2213-2600(13)70119-X URL pmid: 24429244
[26]	Friedrich SO, Venter A, Kayigire XA, et al. Suitability of Xpert MTB/RIF and genotype MTBDRplus for patient selection for a tuberculosis clinical trial. J Clin Microbiol, 2011,49(8):2827-2831. doi: 10.1128/JCM.00138-11. doi: 10.1128/JCM.00138-11 URL
[27]	Shenai S, Ronacher K, Malherbe S, et al. Bacterial loads measured by the Xpert MTB/RIF assay as markers of culture conversion and bacteriological cure in pulmonary TB. PLoS One, 2016,11(8):e0160062. doi: 10.1371/journal.pone.0160062. doi: 10.1371/journal.pone.0160062 URL pmid: 27508390
[28]	Malherbe ST, Shenai S, Ronacher K, et al. Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure. Nat Med, 2016,22(10):1094-1100. doi: 10.1038/nm.4177. doi: 10.1038/nm.4177 URL pmid: 27595324